 |
|
|
|
May 2005 Cover
|
|
Last month the Food and Drug Administration approved Bristol-Myers's Baraclude (entecavir), an oral drug for treatment of chronic hepatitis B. An FDA advisory panel, which unanimously endorsed the approval, found a potential risk of tumors was not significant enough to
outweigh Baraclude's benefits. The drug was put on fast track review after regulators found it addressed a serious unmet need.
Editor's Note: New York Times
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
